Industry

AMBER is differentiated by its excellence of research. Our scientific programmes are focused in areas where we have critical mass of researchers with international reputations. Our objective is to further grow the scientific reputation of the centre in these key areas with a particular focus on multidisciplinary research.

Our business model is focused on the formation of collaborative research partnerships co-funded by industry and this is our primary vehicle for translating our research and expertise into commercial impact.

Since inception, AMBER has built a partner portfolio of over 50 companies and managed over 100 collaborative projects. Our core value proposition is the international competitiveness of our research, coupled to industry-standard project and relationship management. Our approach has been to focus on sectors strongly aligned to our research strengths, targeting companies with a track record in R&D investment.

AMBER’s work with industry focuses on a wide variety of sectors tackling significant industrial challenges. Our industry partners are diverse, both in terms of sectors and scale, working across materials for novel data processing and memory applications, medical devices and regenerative medicine, energy storage and efficiency, carbon capture and green ICT, and industrial technologies, which includes sustainable materials.

A primary objective of the AMBER Centre is to create new knowledge and intellectual property and to successfully transfer that knowledge to industry through licensing agreements, staff exchange and formal transfer of know-how.

AMBER has launched 3 campaigns in the area of Health. Full details can be found in linked brochures below for: Dentistry, Pharma and Foreign Body Response

Dentistry

Dental decay continues to rank as one of the most prevalent global conditions, with toothache persisting as the leading cause for dental visits among both children and adults. This emphasizes the significance of effective endodontic treatment in preserving tooth substance, reinstating functionality, and enhancing overall quality of life. AMBER is investing in the development of Next-Generation Regenerative Dental Restorative Solutions and we’re looking for industry partner(s) to collaborate and co-fund this exciting initiative.

Pharma

The increasing level of knowledge re the genetic basis of disease has opened up the potential to modulate gene expression to enable gene based therapeutic purposes. AMBER are investing up to €2m in the development of Non-Viral gene delivery platforms. Additional opportunity to work with AMBER and NIBRT on development of stable and scalable nanotechnologies for nucleic acid delivery. We are seeking industry partner(s) willing to collaborate on these exciting initiatives with Matched funding.

Foreign Body Response

The foreign body response is thought to be responsible for the failure of one in ten implantable medical devices and to cost up to $10 billion in losses each year. Despite advancements in research and new technologies, the foreign body response remains a huge burden on patients, clinicians and the healthcare system. AMBER is investing in the development of novel solutions against the Foreign Body Response and we’re looking for industry partners to collaborate and co-fund this exciting initiative.